{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Txt":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE335nnn/GSE335568/suppl/filelist.txt"],"Raw":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE335nnn/GSE335568/suppl/GSE335568_RAW.tar"],"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE335nnn/GSE335568/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"species":["Homo sapiens"],"gds_type":["Genome binding/occupancy profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE335568"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"The FGF4–integrin β1 axis orchestrates diabetic wound regeneration by restoring directional collective motility.","description":"This dataset was generated to investigate the mechanisms underlying the pro-healing effects of Fibroblast Growth Factor 4 (FGF4) on diabetic wounds. We performed RNA sequencing on wound tissues from streptozotocin (STZ)-induced diabetic mice. The mice received daily topical applications of either recombinant FGF4 (rFGF4) or PBS vehicle control. Wound tissues were harvested on day 7 post-wounding for transcriptomic analysis.","dates":{"publication":"2026/06/18"},"accession":"GSE335568","cross_references":{"GSM":["GSM9815740","GSM9815738","GSM9815739"],"GPL":["34284"],"GSE":["335568"],"taxon":["Homo sapiens"]}}